US 12,448,435 B2
Anti-TMPRSS6 antibodies and uses thereof
Harvey Chin, Ridgefield, CT (US); Sarah J. Hatsell, Piermont, NY (US); Heinrich Emil Lob, Ossining, NY (US); Andrew J. Murphy, Croton-on-Hudson, NY (US); William Olson, Yorktown Heights, NY (US); Kei Saotome, Englewood, NJ (US); and Bojie Zhang, White Plains, NY (US)
Assigned to REGENERON PHARMACEUTICALS, INC., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on May 10, 2022, as Appl. No. 17/741,234.
Claims priority of provisional application 63/187,150, filed on May 11, 2021.
Prior Publication US 2022/0411487 A1, Dec. 29, 2022
Int. Cl. C07K 16/18 (2006.01); A61K 39/00 (2006.01); A61P 1/16 (2006.01); A61P 7/00 (2006.01); C07K 16/28 (2006.01)
CPC C07K 16/18 (2013.01) [A61P 1/16 (2018.01); A61K 2039/505 (2013.01); A61P 7/00 (2018.01); C07K 16/28 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 16 Claims
 
1. An isolated antibody or antigen-binding fragment thereof that binds specifically to Transmembrane Protease Serine 6 (TMPRSS6) protein,
wherein the antibody or antigen-binding fragment thereof binds to the catalytic domain of TMPRSS6 but does not bind to the catalytic triad of TMPRSS6;
wherein the antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (HCDRs) and three light chain complementarity determining regions (LCDRs),
wherein the three heavy chain CDRs and three light chain CDRs comprise one of the following sets of CDRs:
(a) SEQ ID NO: 4 (HCDR1), SEQ ID NO:6 (HCDR2), SEQ ID NO:8 (HCDR3), SEQ ID NO: 12 (LCDR1), SEQ ID NO:14 (LCDR2), and SEQ ID NO:16 (LCDR3);
(b) SEQ ID NO: 24 (HCDR1), SEQ ID NO:26 (HCDR2), SEQ ID NO:28 (HCDR3), SEQ ID NO:12 (LCDR1), SEQ ID NO: 14 (LCDR2), and SEQ ID NO: 16 (LCDR3);
(c) SEQ ID NO: 34 (HCDR1), SEQ ID NO:36 (HCDR2), SEQ ID NO:38 (HCDR3), SEQ ID NO: 12 (LCDR1), SEQ ID NO: 14 (LCDR2), and SEQ ID NO: 16 (LCDR3);
(d) SEQ ID NO: 44 (HCDR1), SEQ ID NO:46 (HCDR2), SEQ ID NO:48 (HCDR3), SEQ ID NO:52 (LCDR1), SEQ ID NO:54 (LCDR2), and SEQ ID NO:56 (LCDR3);
(e) SEQ ID NO: 64 (HCDR1), SEQ ID NO:66 (HCDR2), SEQ ID NO:68 (HCDR3), SEQ ID NO:72 (LCDR1), SEQ ID NO:74 (LCDR2), and SEQ ID NO: 76 (LCDR3);
(f) SEQ ID NO: 84 (HCDR1), SEQ ID NO:86 (HCDR2), SEQ ID NO:88 (HCDR3), SEQ ID NO:92 (LCDR1), SEQ ID NO:14 (LCDR2), and SEQ ID NO:94 (LCDR3); or
(g) SEQ ID NO: 102 (HCDR1), SEQ ID NO:104 (HCDR2), SEQ ID NO: 106 (HCDR3), SEQ ID NO: 110 (LCDR1), SEQ ID NO: 14 (LCDR2), and SEQ ID NO: 112 (LCDR3).